newsPharming extends Ruconest distribution agreement with Cytobioteck9 February 2016 | By Victoria WhiteUnder the extended agreement, Cytobioteck will also exclusively distribute Ruconest in Argentina, Costa Rica, the Dominican Republic and Panama...
newsPharming completes patient enrolment in Phase 2 Ruconest trial6 January 2016 | By Victoria WhitePharming has completed patient enrolment in the Phase 2 clinical study of Ruconest (recombinant C1 esterase Inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).
newsFDA grants HAE drug Ruconest 12-years of exclusivity8 October 2015 | By Victoria WhiteThe exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...